Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:SAFE
NYSE:SAFESpecialized REITs

Safehold Targets Value Unlock After S&P Upgrade And Buyback Launch

Safehold (NYSE:SAFE) received an S&P credit rating upgrade to A- with a stable outlook. The company announced a share buyback program alongside plans to monetize more of its unrealized capital appreciation, known as "Carats." Management outlined an expansion of ground lease originations, including a focus on affordable housing and broader geographic reach. Safehold, trading at $14.84, is working to reposition itself in the eyes of both credit markets and equity investors. The stock is up...
OM:CAMX
OM:CAMXPharmaceuticals

Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress

Camurus AB reported its fourth-quarter and full-year 2025 results, with full-year sales rising to SEK 2,265.38 million and net income to SEK 735.57 million, while issuing 2026 guidance for revenues of SEK 2.60–2.90 billion and operating result of SEK 0.90–1.20 billion. Alongside these results, Camurus highlighted 2025 milestones including EU and UK approvals for Oxyesa in acromegaly and progress in long-acting metabolic therapies, underlining how its product pipeline and regulatory traction...
NYSE:NABL
NYSE:NABLSoftware

N-able’s Empower 2026 Puts Cyber Resilience And MSP Ties In Focus

N-able (NYSE:NABL) announced its Empower 2026 conference, centered on business resilience in cybersecurity. The event will spotlight emerging technology trends, expanded technical tracks, and interactive workshops. Empower 2026 is positioned as a forum for business leaders and IT professionals to address evolving cyber risks. N-able, known for its software solutions that support managed service providers and IT teams, is using Empower 2026 to put cybersecurity resilience front and center...
NasdaqGM:AVDL
NasdaqGM:AVDLPharmaceuticals

Assessing Avadel Pharmaceuticals (AVDL) Valuation As Shares Hover Near US$21 After Strong One Year Return

Avadel Pharmaceuticals (AVDL) has drawn investor attention after recent trading left the shares around $21.64, prompting fresh interest in how its narcolepsy focused portfolio and current fundamentals line up for long term holders. See our latest analysis for Avadel Pharmaceuticals. While the recent 1 day share price return of around 0.05% at US$21.64 and a 30 day share price return of 0.65% suggest only modest short term movement, the 1 year total shareholder return of 151.34% points to...
TSE:7276
TSE:7276Auto Components

Is Koito’s Profit‑Focused Global Restructuring Altering The Investment Case For Koito Manufacturing (TSE:7276)?

Koito Manufacturing Co., Ltd. recently reported nine‑month results to December 31, 2025, with higher sales of ¥690,005 million but lower net income of ¥23,056 million compared with the prior year. At the same time, the company issued guidance for the fiscal year ending March 31, 2026 that combines an expected decline in net sales with higher operating profit driven by productivity gains, cost reductions, and a global restructuring of its production system. We will now examine how Koito’s...
ASX:BML
ASX:BMLMetals and Mining

A Look At Boab Metals (ASX:BML) Valuation As Sorby Hills Secures Final Construction Approvals

Boab Metals (ASX:BML) has moved into focus after securing final works approvals for full construction at its Sorby Hills silver, lead and zinc project, marking a key step toward potential future production. See our latest analysis for Boab Metals. Those approvals and recent capital moves, including a A$60m follow on equity offering at A$0.40 and new director shares tied to Sorby Hills permits, come after strong momentum. The company has recorded a 90 day share price return of 52.38% and a...
ENXTAM:PRX
ENXTAM:PRXMultiline Retail

Is Prosus (ENXTAM:PRX) Starting To Look Attractive After Recent Share Price Slide?

If you are wondering whether Prosus is starting to look like value or a value trap at around €42.76 per share, you are not alone. That is exactly what this article will unpack. The stock has seen a 5.9% decline over the last 7 days, a 22.9% decline over the last 30 days and a 20.5% decline year to date, even though the 1 year return is 4.4% and the 3 year return is 25.6%, while the 5 year return sits at a 12.9% decline. Recent news flow around Prosus has focused on its broad portfolio of...
NasdaqGS:CRTO
NasdaqGS:CRTOMedia

Criteo’s New AI Service Tests Investor Patience And Valuation Gap

Criteo has introduced its Agentic Commerce Recommendation Service, an AI-driven product for shopping assistants. The service uses Criteo’s commerce intelligence and real-world shopping data to generate personalized product recommendations. The launch is aimed at retailers and platforms looking to embed higher quality recommendation engines into online shopping journeys. Criteo, listed on NasdaqGS:CRTO, is rolling out this new service at a time when its share price stands at $18.21. The...
TSX:CAR.UN
TSX:CAR.UNResidential REITs

CAPREIT’s 2025 Portfolio Shakeup Tests Growth And Earnings Resilience

CAPREIT (TSX:CAR.UN) completed $2b in transaction volume in 2025. The activity included sizeable acquisitions and the sale of non core Canadian properties. Management framed the moves as part of a focused effort to improve portfolio quality and long term stability. Canadian Apartment Properties REIT is a major player in the Canadian residential rental market, with a portfolio centered on income producing properties. Its latest $2b of transactions comes as investors are watching how large...
ASX:JHX
ASX:JHXBasic Materials

Why James Hardie Industries (ASX:JHX) Is Up 12.6% After Beating Adjusted Q3 Earnings Expectations

In the past quarter, James Hardie Industries plc reported third-quarter 2025 sales of US$1,239.8 million, up from US$953.3 million a year earlier, while net income fell to US$68.7 million from US$141.7 million and basic earnings per share from continuing operations declined to US$0.12 from US$0.33. Despite the weaker headline profit, the company exceeded analyst expectations for adjusted earnings and revenue, highlighting strong sales growth supported by the early benefits of its AZEK...
NasdaqGS:SSNC
NasdaqGS:SSNCProfessional Services

SS&C Wins Saltus And Allspring Mandates As Valuation Gap Widens

SS&C Technologies Holdings agreed a long term technology partnership with Saltus to support automation and consolidation across its wealth management platform. The company also expanded its transfer agency agreement with Allspring Global Investments, broadening investor servicing for the asset manager. These new and expanded mandates highlight demand for SS&C’s scalable, integrated and regulatory focused solutions across wealth and asset management. For investors tracking NasdaqGS:SSNC, the...
TSX:LGO
TSX:LGOMetals and Mining

Largo (TSX:LGO) Valuation Check After New Production Guidance And Ferrovanadium Market Update

Largo (TSX:LGO) is back on investors radar after a series of early February updates. These include fresh production guidance, detailed mine results, and a reminder of its role in a tight ferrovanadium market. See our latest analysis for Largo. Largo’s early February production guidance and ferrovanadium market update came alongside sharp share price swings, with a 90 day share price return of 55.97% but a 1 year total shareholder return decline of 19.62%, suggesting short term momentum...
TSX:FTT
TSX:FTTTrade Distributors

Is It Too Late To Consider Finning International (TSX:FTT) After A 103% One-Year Surge?

If you are wondering whether Finning International's share price still reflects good value after a strong run, you are not alone. This article will walk through what the numbers actually say. The stock last closed at C$87.20, with returns of 1.0% over 7 days, 7.3% over 30 days, 15.9% year to date, 103.0% over 1 year and 161.4% over 3 years. This naturally raises questions about how much of the story is already priced in. Recent coverage has focused on Finning International's position in...
NasdaqCM:MBOT
NasdaqCM:MBOTMedical Equipment

Assessing Microbot Medical (MBOT) Valuation As LIBERTY Robotic System Advances Toward Full Market Release

Microbot Medical (MBOT) is coming into focus as its LIBERTY Endovascular Robotic System moves from a U.S. limited market release toward a planned full market rollout, supported by fresh exposure at a key industry conference. See our latest analysis for Microbot Medical. Recent trading reflects a mix of excitement and caution, with a 29.01% 7 day share price return and a modest 0.97% 90 day share price return sitting against a 5 year total shareholder return loss of 78.95%. Momentum therefore...